Search results
PROMOTED
Stay up to date with the latest clinical evidence in transthyretin amyloid cardiomyopathy (ATTR-CM) with this video series spotlighting key cardiomyopathy updates presented at ESC Heart Failure Congress (HFA) 2026.In the first session, Dr Mathew Maurer (Columbia University, New York, US) takes a deep dive into the CARDIO-TTRansform data, exploring the current treatment landscape and ongoing unmet…
View more
Spotlight on HFA 2026: Updates on Cardiomyopathies
Added:
3 weeks ago
Video Series
ARNI for Optimising HFrEF Management
Added:
10 months ago
Expert Opinion
Added:
7 months ago
AHA Scientific Sessions 2025 - Dr Nils Krüger (Brigham and Women's Hospital, US) joins us to discuss findings from the TIRZSEMA-CVOT (NCT07096063) study, examining real-world cardiovascular outcomes with tirzepatide and semaglutide in patients with type 2 diabetes at cardiovascular risk.This retrospective cohort study utilized three national US claims databases to evaluate over 887,000 patients…
View more
Lipoprotein(a): A Risk Factor and Biomarker in Heart Failure
Added:
1 month ago
Review Article
Genetics in Hypertrophic Cardiomyopathy
Added:
3 months ago
Review Article
VAC in HFpEF: Trends and Challenges
Added:
6 months ago
Review Article
Reverse Remodelling in HFrEF
Added:
5 months ago
Review Article
Added:
2 years ago
HFA 2024 — Dr Tauben Averbuch and Dr Harriette Van Spall (McMaster University, Hamilton, CA) discuss the findings from the PACT-HF trial. In this analysis of PACT-HF, investigators looked at long term sex-specific clinical outcomes and healthcare resource utilisation following hospitalisation for heart failure at 5 years.Findings shows that clinical outcomes and overall costs were similar between…
View more
Added:
9 months ago
Added:
1 year ago